Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Crinetics Pharmaceuticals (Nasdaq: CRNX) will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after market close.
Rhea-AI Summary
Crinetics Pharmaceuticals (Nasdaq: CRNX) will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after market close.
Management will host a conference call and webcast the same day at 4:30 p.m. ET to discuss results and provide a business update. Dial-in numbers and an access code are provided for domestic and international participants, and a live webcast will be available and later archived on the company’s Investor Relations website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CRNX
In the Jan 27 session, CRNX gained 0.85%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings date
- February 26, 2026
- Q4 and full-year 2025 results release after market close
- Conference time
- 4:30 p.m. ET
- Scheduled earnings conference call start time
- Domestic dial-in
- 1-833-470-1428
- U.S. access number for earnings call
- International dial-in
- 1-646-844-6383
- International access number for earnings call
- Access code
- 027322
- Conference call access code for participants
Historical Context
-
Disclosed stock options and RSUs granted to new non-executive employees.
-
Underwritten public offering of 7,620,000 shares at $45.95 per share.
-
Announced intent to raise $350.0M in an underwritten common stock offering.
-
Positive Phase 2 atumelnant data and early PALSONIFY U.S. net product revenue.
-
Announced business update and topline Phase 2 atumelnant results webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Conference Call & Webcast
Thursday, February 26 at 4:30 p.m. ET
| Domestic: | 1 833-470-1428 | |
| International: | 1 646-844-6383 | |
| Access Code: | 027322 | |
Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.
The webcast will be archived on the Investor Relations section of www.crinetics.com.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.